Histiocytosis

There are 5 clinical trials for histiocytosis, of which 5 are open and 0 are completed or closed. Of the trials that contain histiocytosis as an inclusion criterion, 4 are phase 2 (4 open) and 1 is phase 3 (1 open).

ACBD5-RET, AFAP1L2-RET, and CCDC6-RET are the most frequent gene inclusion criteria for histiocytosis clinical trials [3].

Trials Investigating Histiocytosis by Gene and Recruiting Status

Ivosidenib, selpercatinib, and tipifarnib are the most common interventions in histiocytosis clinical trials.

Drugs Being Investigated in Histiocytosis Trials by Recruiting Status

Significant Genes in Histiocytosis

ACBD5 +

ACBD5 is an inclusion eligibility criterion in 1 clinical trial for histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains ACBD5 status and histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [3].

AFAP1L2 +

AFAP1L2 is an inclusion eligibility criterion in 1 clinical trial for histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains AFAP1L2 status and histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF +

BRAF is an inclusion eligibility criterion in 1 clinical trial for histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [3].

CCDC6 +

CCDC6 is an inclusion eligibility criterion in 1 clinical trial for histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains CCDC6 status and histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [3].

CEP43 +

CEP43 is an inclusion eligibility criterion in 1 clinical trial for histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains CEP43 status and histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [3].

ERC1 +

ERC1 is an inclusion eligibility criterion in 1 clinical trial for histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains ERC1 status and histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [3].

GOLGA5 +

GOLGA5 is an inclusion eligibility criterion in 1 clinical trial for histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains GOLGA5 status and histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [3].

HOOK3 +

HOOK3 is an inclusion eligibility criterion in 1 clinical trial for histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains HOOK3 status and histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [3].

HRAS +

HRAS is an inclusion eligibility criterion in 1 clinical trial for histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [3].

IDH1 +

IDH1 is an inclusion eligibility criterion in 1 clinical trial for histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [3].

KIAA1217 +

KIAA1217 is an inclusion eligibility criterion in 1 clinical trial for histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains KIAA1217 status and histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [3].

KIF5B +

KIF5B is an inclusion eligibility criterion in 1 clinical trial for histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains KIF5B status and histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [3].

NCOA4 +

NCOA4 is an inclusion eligibility criterion in 1 clinical trial for histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains NCOA4 status and histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [3].

PPFIBP2 +

PPFIBP2 is an inclusion eligibility criterion in 1 clinical trial for histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains PPFIBP2 status and histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [3].

PRKAR1A +

PRKAR1A is an inclusion eligibility criterion in 1 clinical trial for histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains PRKAR1A status and histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [3].

RET +

RET is an inclusion eligibility criterion in 1 clinical trial for histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains RET status and histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [3].

RUFY1 +

RUFY1 is an inclusion eligibility criterion in 1 clinical trial for histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains RUFY1 status and histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [3].

TFG +

TFG is an inclusion eligibility criterion in 1 clinical trial for histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains TFG status and histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [3].

TRIM27 +

TRIM27 is an inclusion eligibility criterion in 1 clinical trial for histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains TRIM27 status and histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [3].

Disease Details

Synonyms

PEDIATRIC Soft tissue histiocytosis (NOS), Soft tissue histiocytosis (NOS), Histiocytic Infiltrate, Histiocytic Syndrome

Parent(s)

Histiocytic and Dendritic Cell Neoplasm

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

Histiocytosis

Back to Diseases List

Associated Genetic Biomarkers

Overview

Clinical Trials

Significant Genes in Histiocytosis

Disease Details

References

About

Molecular Medicine

Content Types